Reporting behavior may be influenced by event severity, regulatory actions, and clinical awareness, potentially leading to an overrepresentation of serious adverse events and underreporting of milder events
The Indian government plans to offer incentives to promote local manufacturing of GLP-1 drugs by 2026, which will impact pricing and availability. Brazil In Brazil, the first generics of semaglutide (Ozempic) will launch in March 2026 after Novo Nordisks patent expires
thetaiotaomicron are capable of suppressing GLP-1 levels and, most importantly, locomotion in an antibiotic-treated mouse model, we first tested locomotor activity in ampicillin-treated mice following the previously described procedure (Fig
Does this article recommend BPC-157
In this narrative review, we discuss GI complications of MAFLD and their association with obesity as the prime focus of interest
The main job of this page is safety and side-effect planning, especially where the topic touches side effects